AppTec
WuXi AppTec Divests Cell and Gene Therapy Units to Altaris in Strategic Shift
WuXi AppTec, Cell and Gene Therapy, Altaris, Strategic Divestment, Biosecure Act, Pharmaceutical Outsourcing
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying
WuXi AppTec Continues to Attract New Clients Amid BIOSECURE Act Uncertainty
WuXi AppTec, BIOSECURE Act, new clients, revenue decline, Chinese contract manufacturer, U.S. Senate consideration, pharmaceutical industry, supply chain vulnerabilities.
WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects
BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns
WuXi AppTec and WuXi Biologics Consider Asset Sales Amid BIOSECURE Act Scrutiny
WuXi AppTec, WuXi Biologics, BIOSECURE Act, asset sales, biotech industry, US-China relations
WuXi AppTec Unfazed by BIOSECURE Act Threat, Secures New US Deals
WuXi AppTec, BIOSECURE Act, US Deals, Pharmaceutical Manufacturing, Biotech Industry
WuXi AppTec Faces Revenue Decline Amid Looming BIOSECURE Act Threat
WuXi AppTec, BIOSECURE Act, Revenue Decline, Biotechnology, US-China Relations